FDA Approved Drug Products: Tecentriq (atezolizumab) injection for intravenous use (May 2023) [Link] External Links KEGG Drug D10773 PubChem Substance 347911207 RxNav 1792776 RxList RxList Drug Page Drugs.com Drugs.com Drug Page Wikipedia Atezolizumab FDA label Download (245 KB) Clinical Trial...
An open-label, Phase I/Ib study investigating the safety and efficacy of tiragolumab + atezolizumab + RadScopal™ XRT in patients with metastatic solid malignancies. 开始日期2025-06-30 申办/合作机构 The University of Texas MD Anderson Cancer Center ...
FDA The FDA has approved atezolizumab (Tecentriq) for adult and pediatric patients aged 2 years and older with unresectable or metastatic alveolar soft part sarcoma (ASPS). The safety and efficacy of the agent was examined in the open-label, single-arm study, referred to as Study ML39345 ...
The open-label, phase 2 trial enrolled patients with advanced nonsquamous NSCLC with untreated brain metastases who did not have neurologic symptoms or were asymptomatic with medical treatment. Patients were aged 18 years and older, had to have an ECOG performance status of 0-1, adequate bone m...
1. Testing atezolizumab alone or atezolizumab plus bevacizumab in people with advanced alveolar soft part sarcoma. ClinicalTrials.gov. Updated April 18, 2023. Accessed April 26, 2023. https://bit.ly/3mXh3HK 2. FDA grants approval to atezolizumab for alveolar soft part sarcoma. News release. ...
(NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA-approved test, with noEGFRor ALK genomic tumor ...
FDA-approved anti-PD-L1 antibody drug Atezolizumab is a human IgG1 without glycosylation by an N297A mutation. Aglycosylation of IgG1 has been used to completely remove the unwanted Fc-mediated functions such as antibody-dependent cytotoxicity (ADCC). Ho
Background The cancer-cell-killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor-mediated immunosuppression with bevacizumab. This open-label, phase 3 study evaluated atezolizumab plus bevacizumab plus chemotherapy in patients with metastatic nonsquamous non-...
January 17, 2021 - The combination of atezolizumab and bevacizumab continued to display improved survival compared with sorafenib in previously untreated patients with advanced hepatocellular carcinoma.
The multicenter, open-label, phase 1b COSMIC-021 trial is evaluating the combination of the PD-L1 inhibitor atezolizumab and the multikinase inhibitor cabozantinib in patients with locally advanced or metastatic solid tumors. The mCRPC cohort is cohort 6 of the trial. Patients in this cohort were...